Basic science inspires conference goers in Chicago.
White-matter hyperintensities, astrocyte damage, hypoperfusion, and amyloid angiopathy draw scrutiny as factors in the complex relationship between cerebrovascular and neurodegenerative processes in dementia.
Scientists struggle to understand neurodegeneration in the SNAP syndrome.
Scanning for amyloid plaques in the brain may help clinicians diagnose and manage patients with a questionable diagnosis of Alzheimer’s.
The largest trial yet of ApoE4 carriers is pioneering new protocols with increasing use of technology to reach thousands of potential participants and disclose risk information.
Prevention trials are testing new protocols for telling potential participants about their heightened risk for dementia, and exploring the psychological effect of such disclosures.
The synaptic protein abounds in the cerebrospinal fluid of AD patients and in those in the prodromal phase of the disease.
Research uncovers subtle links between early development problems and some forms of dementia.
Variability still plagues CSF biomarker measurements, but automated systems offer hope of a diagnostic assay.
Scientists are coming to grips with how tau spreads, and what the consequences are for the brain.
Researchers report multiple benefits of aerobic exercise on brain function, including some hints it could slow tau pathology.
At the right intensity and treatment duration, aerobic exercise can sharpen thinking skills and improve brain function even in cognitively impaired people, say researchers.
At AAIC, new data on three anti-Aβ antibodies reinforced a sense of hope that Aβ immunotherapy may yet work out. Challenges with each antibody notwithstanding, all four leading candidates, including crenezumab, are now in Phase 3.
Tiny injuries to capillaries in white matter, and to cells in gray matter, have come to be the focus of new imaging measures being explored in early presymptomatic AD.
Regulatory and pharma scientists fielded pleas from families with autosomal-dominant Alzheimer’s disease just prior to the AAIC conference.